Incyte nabs 2nd ever approval ahead of schedule as FDA insists it can still review on time

Almost a full year after Incyte broke off a troubled partnership with Eli Lilly to focus on its own internal engine, one of the drugs from that engine will enter the market.

Pemigatinib, now branded as Pemazyre, obtained FDA approval as a second-line treatment for a rare form of cancer known as cholangiocarcinoma, or bile duct cancer.